DFTX Stock Surges on White House Psychedelic Push

Definium Therapeutics (DFTX) stock rises sharply as the White House advances initiatives on psychedelic treatments, signaling a potential breakthrough in mental health and veteran care options. This move prioritizes innovative therapies over big pharma's stranglehold and FDA red tape, putting American patients first by exploring substances like psilocybin for PTSD and depression that show real promise in trials. Read more about this...